Ignite Creation Date:
2024-05-06 @ 12:34 PM
Last Modification Date:
2024-10-26 @ 1:01 PM
Study NCT ID:
NCT03797326
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-10-31
First Post:
2019-01-07
Brief Title:
Efficacy and Safety of Pembrolizumab MK-3475 Plus Lenvatinib E7080MK-7902 in Previously Treated Participants With Select Solid Tumors MK-7902-005E7080-G000-224LEAP-005
Sponsor:
Organization:
Merck Sharp Dohme LLC
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
590
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: